`571-272-7822
`
`Paper 27
`Date: October 11, 2023
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED,
`Patent Owner.
`
`IPR2022-01104
`Patent 9,919,024 B2
`
`
`
`
`
`
`
`
`
`Before SHERIDAN SNEDDEN, CYNTHIA M. HARDMAN, and
`MICHAEL A. VALEK, Administrative Patent Judges.
`
`SNEDDEN, Administrative Patent Judge.
`
`DECISION
`Granting Patent Owner’s Motion to Expunge
`37 C.F.R. §§ 42.14, 42.56
`
`
`
`
`
`
`
`
`
`IPR2022-01104
`Patent 9,919,024 B2
`
`Patent Owner filed a motion to expunge the confidential versions of
`
`Exhibit 2013 (confidential version of Clinical Study Report) and Paper 7
`
`(confidential version of Patent Owner’s Preliminary Response, which
`
`discusses the Clinical Study Report). See Paper 20 (“Motion”). Petitioner
`
`did not oppose the Motion. For the reasons stated below, we grant the
`
`Motion.
`
`The Board previously sealed Exhibit 2013 and Paper 7. See Paper 15,
`
`19–20. The record contains redacted versions of these documents. See
`
`Mot. 3. Unless the Board grants a motion to expunge, confidential exhibits
`
`will ordinarily become public 45 days after denial of a petition to institute a
`
`trial. See Patent Trial and Appeal Board Consolidated Trial Practice Guide
`
`(November 2019) (“Trial Practice Guide”)1 21–22. This is because a strong
`
`public policy exists for making public all information filed in our
`
`administrative trial proceedings. 37 C.F.R. § 42.14. Thus, we resolve the
`
`Motion by balancing the public’s interest in maintaining a complete and
`
`understandable record against a party’s demonstrated interest in protecting
`
`truly sensitive, confidential information. Trial Practice Guide 22.
`
`Patent Owner correctly avers that the Board “did not cite anything
`
`exclusively in the confidential documents in its decision denying institution
`
`of the inter partes review.” Mot. 4. Additionally, we are persuaded that the
`
`details of the sealed confidential information are not necessary to an
`
`understanding of the reasons supporting our decision to deny institution. As
`
`such, we find that the public’s interest in access to those details is minimal,
`
`and we accept Patent Owner’s unopposed argument that good cause exists to
`
`expunge the confidential versions of Exhibit 2013 and Paper 7.
`
`
`1 Available at https://www.uspto.gov/TrialPracticeGuideConsolidated.
`
`2
`
`
`
`IPR2022-01104
`Patent 9,919,024 B2
`
`Accordingly, we grant Patent Owner’s Motion to Expunge.
`
`It is
`
`ORDERED that Patent Owner’s Motion to Expunge is granted; and
`
`FURTHER ORDERED that the confidential versions of Exhibit 2013
`
`and Paper 7 are expunged.
`
`3
`
`
`
`IPR2022-01104
`Patent 9,919,024 B2
`
`FOR PETITIONER:
`
`Jad Mills
`Richard Torczon
`Nicole Stafford
`Dennis Gregory
`WILSON SONSINI GOODRICH & ROSATI
`jmills@wsgr.com
`rtorczon@wsgr.com
`nstafford@wsgr.com
`dgregory@wsgr.com
`
`
`FOR PATENT OWNER:
`
`Justin J. Hasford
`Bryan C. Diner
`Joshua L. Goldberg
`Caitlin E. O’Connell
`Kyu Yun Kim
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, L.L.P.
`justin.hasford@finnegan.com
`bryan.diner@finnegan.com
`lauren.robinson@finnegan.com
`connell@finnegan.com
`kyuyun.kim@finnegan.com
`
`
`
`4
`
`